Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression and ex vivo drug r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:NPJ Precis Oncol
Egile Nagusiak: White, Brian S., Khan, Suleiman A., Mason, Mike J., Ammad-ud-din, Muhammad, Potdar, Swapnil, Malani, Disha, Kuusanmäki, Heikki, Druker, Brian J., Heckman, Caroline, Kallioniemi, Olli, Kurtz, Stephen E., Porkka, Kimmo, Tognon, Cristina E., Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8302655/
https://ncbi.nlm.nih.gov/pubmed/34302041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00209-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak